Literature DB >> 11751123

Efficacy of short-course ceftriaxone therapy for Borrelia burgdorferi infection in C3H mice.

Charles Pavia1, Mario A Inchiosa, Gary P Wormser.   

Abstract

Ceftriaxone is highly effective clinically in patients with Lyme disease. We studied a representative invasive human isolate of Borrelia burgdorferi for which the MBC of ceftriaxone was 0.050 microg/ml. A once-per-day dosage regimen of ceftriaxone (50 mg/kg/dose) administered intramuscularly for 5 days was 100% effective in sterilizing tissue samples of C3H mice infected with this strain of B. burgdorferi, regardless of whether the mice were being treated concomitantly with a corticosteroid. Administration of the same five doses of ceftriaxone at 6-h intervals over just 24 h was also 100% effective. These experiments suggest that shorter courses of antibiotics than those currently recommended should be considered for study in patients with early uncomplicated Lyme disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11751123      PMCID: PMC126994          DOI: 10.1128/AAC.46.1.132-134.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Efficacy of SCH27899 in an animal model of Legionnaires' disease using immunocompromised A/J mice.

Authors:  J K Brieland; D Loebenberg; F Menzel; R S Hare
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

2.  Practice guidelines for the treatment of Lyme disease. The Infectious Diseases Society of America.

Authors:  G P Wormser; R B Nadelman; R J Dattwyler; D T Dennis; E D Shapiro; A C Steere; T J Rush; D W Rahn; P K Coyle; D H Persing; D Fish; B J Luft
Journal:  Clin Infect Dis       Date:  2000-07       Impact factor: 9.079

3.  Impact of genotypic variation of Borrelia burgdorferi sensu stricto on kinetics of dissemination and severity of disease in C3H/HeJ mice.

Authors:  G Wang; C Ojaimi; R Iyer; V Saksenberg; S A McClain; G P Wormser; I Schwartz
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

4.  Determination of ceftriaxone, a novel cephalosporin, in plasma, urine and saliva by high-performance liquid chromatography on an NH2 bonded-phase column.

Authors:  V Ascalone; L Dal Bò
Journal:  J Chromatogr       Date:  1983-04-08

5.  Borrelia recurrentis infection: single-dose antibiotic regimens and management of the Jarisch-Herxheimer reaction.

Authors:  T Butler; P K Jones; C K Wallace
Journal:  J Infect Dis       Date:  1978-05       Impact factor: 5.226

6.  Activity of sera from patients with Lyme disease against Borrelia burgdorferi.

Authors:  C S Pavia; G P Wormser; G L Norman
Journal:  Clin Infect Dis       Date:  1997-07       Impact factor: 9.079

7.  Efficacy of an evernimicin (SCH27899) in vitro and in an animal model of Lyme disease.

Authors:  C S Pavia; G P Wormser; J Nowakowski; A Cacciapuoti
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

8.  In vivo activity and pharmacokinetics of ziracin (SCH27899), a new long-acting everninomicin antibiotic, in a murine model of penicillin-susceptible or penicillin-resistant pneumococcal pneumonia.

Authors:  E Wang; M Simard; Y Bergeron; D Beauchamp; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

9.  Failure of treatment with cephalexin for Lyme disease.

Authors:  J Nowakowski; D McKenna; R B Nadelman; D Cooper; S Bittker; D Holmgren; C Pavia; R C Johnson; G P Wormser
Journal:  Arch Fam Med       Date:  2000-06

10.  Reactivation of Chlamydia trachomatis lung infection in mice by cortisone.

Authors:  Y S Yang; C C Kuo; W J Chen
Journal:  Infect Immun       Date:  1983-02       Impact factor: 3.441

View more
  9 in total

1.  Spirochete antigens persist near cartilage after murine Lyme borreliosis therapy.

Authors:  Linda K Bockenstedt; David G Gonzalez; Ann M Haberman; Alexia A Belperron
Journal:  J Clin Invest       Date:  2012-06-25       Impact factor: 14.808

2.  Culture of the entire mouse to determine whether cultivable Borrelia burgdorferi persists in infected mice treated with a five-day course of Ceftriaxone.

Authors:  Charles S Pavia; Gary P Wormser
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

Review 3.  Antibiotic treatment of animals infected with Borrelia burgdorferi.

Authors:  Gary P Wormser; Ira Schwartz
Journal:  Clin Microbiol Rev       Date:  2009-07       Impact factor: 26.132

4.  Ineffectiveness of tigecycline against persistent Borrelia burgdorferi.

Authors:  Stephen W Barthold; Emir Hodzic; Denise M Imai; Sunlian Feng; Xiaohua Yang; Benjamin J Luft
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

5.  Intraarticular corticosteroids in refractory childhood Lyme arthritis.

Authors:  S Nimmrich; I Becker; G Horneff
Journal:  Rheumatol Int       Date:  2014-01-04       Impact factor: 2.631

6.  Persistent arthritis in Borrelia burgdorferi-infected HLA-DR4-positive CD28-negative mice post-antibiotic treatment.

Authors:  Bettina Panagiota Iliopoulou; Joseph Alroy; Brigitte T Huber
Journal:  Arthritis Rheum       Date:  2008-12

7.  Detection of Borrelia burgdorferi nucleic acids after antibiotic treatment does not confirm viability.

Authors:  Radha Iyer; Priyanka Mukherjee; Kemeng Wang; Joshua Simons; Gary P Wormser; Ira Schwartz
Journal:  J Clin Microbiol       Date:  2012-12-26       Impact factor: 5.948

8.  Outer surface protein A protects Lyme disease spirochetes from acquired host immunity in the tick vector.

Authors:  James M Battisti; James L Bono; Patricia A Rosa; Merry E Schrumpf; Tom G Schwan; Paul F Policastro
Journal:  Infect Immun       Date:  2008-09-08       Impact factor: 3.441

9.  Identification of new drug candidates against Borrelia burgdorferi using high-throughput screening.

Authors:  Venkata Raveendra Pothineni; Dhananjay Wagh; Mustafeez Mujtaba Babar; Mohammed Inayathullah; David Solow-Cordero; Kwang-Min Kim; Aneesh V Samineni; Mansi B Parekh; Lobat Tayebi; Jayakumar Rajadas
Journal:  Drug Des Devel Ther       Date:  2016-04-01       Impact factor: 4.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.